| 引用本文:许晶，侯丽，李冬云，杨茜茹，王婧.西黄胶囊联合化疗治疗恶性肿瘤的系统评价和Meta分析[J].世界中医药,2023,(05):. |
|
| 西黄胶囊联合化疗治疗恶性肿瘤的系统评价和Meta分析 |
| A Systematic Review and Meta-analysis of Xihuang Capsules Combined with Chemotherapy Against Malignant Tumors |
| 投稿时间：2021-06-09 |
| DOI：10.3969/j.issn.1673-7202.2023.05.006 |
| 中文关键词: 西黄胶囊 化疗 恶性肿瘤 Meta分析 有效性 安全性 随机对照试验 不良反应 |
| English Keywords:Xihuang Capsules Chemotherapy Malignant tumor Meta-analysis Efficacy Safety Randomized controlled trial Adverse reactions |
| 基金项目:国家自然科学基金青年基金项目（81503575）；首都卫生发展科研专项项目(2020-2-4193) |
|
| 摘要点击次数: 490 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评价西黄胶囊联合化疗治疗恶性肿瘤的临床疗效和安全性。方法：首先全面检索国家知识基础设施数据库（CNKI）、中文科技期刊数据库（CCD）、中国学术期刊数据库（CSPD）、中国生物医学文献数据库（CBM)、PubMed、Web of Science和Medline数据库，检索时间至2020年6月，然后按拟定的纳入标准筛选西黄胶囊联合化疗治疗恶性肿瘤的随机对照试验（RCTs）进行Meta分析。结果：共检索出395篇相关文献，最终纳入16个RCTs，总共包含1 288例患者。Meta分析结果发现：西黄胶囊联合化疗可提高消化道肿瘤（食管癌、胃癌、结肠癌）、肺癌和乳腺癌的总有效率（RR）和疾病控制率（DCR），并未提高宫颈癌的临床疗效，因纳入研究数量的限制，运用宫颈癌结论时需慎重。此外，研究发现西黄胶囊联合化疗可提高患者的卡诺夫斯凯计分（KPS）评分，改善CD3+、CD4+及CD4+/CD8+等免疫功能指标，且可减少血小板和Ⅲ~Ⅳ度白细胞下降及肝肾损害的发生率，但对胃肠道反应发生率、血红蛋白和Ⅰ~Ⅱ度白细胞减少无改善。结论：西黄胶囊联合化疗可提高恶性肿瘤患者的临床疗效，降低肝肾损害和血小板下降的发生率，研究结论需更多高质量的RCTs验证。 |
| English Summary: |
| To evaluate the clinical efficacy and safety of Xihuang Capsules combined with chemotherapy in the treatment of malignant tumors.Methods:CNKI，CCD，CSPD，CBM，PubMed，Web of Science，and Medline databases were searched comprehensively for randomized controlled trials(RCTs) of Xihuang Capsules combined with chemotherapy for malignant tumors from database inception to June 2020 according to the preset inclusion criteria，followed by Meta-analysis.Results:A total of 395 research articles were initially retrieved，and finally 16 RCTs were included，involving 1 288 samples.The meta-analysis found that Xihuang Capsules combined with chemotherapy could improve the total response rate(RR) and disease control rate(DCR) of gastrointestinal cancers(esophageal cancer，gastric cancer，and colon cancer)，lung cancer，and breast cancer，but the clinical efficacy of cervical cancer was not improved.Due to the limitation of the number of studies，their usage in cervical cancer conclusions should be cautious.In addition，this study also found that Xihuang Capsules combined with chemotherapy could improve the KPS score and immune function indicators such as CD3+，CD4+，and CD4+/CD8+，and reduce the incidence of decrease in blood platelets and Ⅲ～Ⅳ° white blood cells and liver and kidney damage.However，there was no improvement in the incidence of gastrointestinal reactions，reduction in hemoglobin，and Ⅰ~Ⅱ° white blood cells.Conclusion:Xihuang Capsules combined with chemotherapy can improve the clinical efficacy of patients with malignant tumors and reduce the incidence of liver and kidney damage and thrombocytopenia.The conclusion of this study needs more high-quality RCTs for verification. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
